Categories: NewsPharmaceutical

Investors in Common Stock and Certain Debt Securities Offered by Valeant Pharmaceuticals International, Inc. May be Entitled to Payment from an SEC Fair Fund

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WASHINGTON, Oct. 19, 2024 /PRNewswire/ — The following statement is being issued regarding the Valeant Pharmaceuticals Fair Fund.

UNITED STATES SECURITIES AND
EXCHANGE COMMISSION

 

In the Matter of

 

Valeant Pharmaceuticals International, Inc. n/k/a
Bausch Health Companies Inc.; J. Michael Pearson;
Howard B. Schiller; and Tanya R. Carro, CPA,

 

Respondents.

 

ADMINISTRATIVE PROCEEDING
File Nos. 3-19899, 3-19900, 3-19901, and 3-19902

 

Valeant Pharmaceuticals Fair Fund 

SUMMARY DISTRIBUTION PLAN NOTICE

The United States Securities and Exchange Commission authorized this Notice. 

This is not a solicitation from a lawyer.

 

Who is Eligible to Participate in the Fair Fund?

If you purchased or otherwise acquired Valeant Pharmaceuticals International, Inc. (“Valeant”) common stock between October 20, 2014 and April 28, 2016, inclusive, or certain bonds issued by Valeant identified in Exhibit A of the Corrected Plan of Distribution (the “Plan”) between October 20, 2014 and October 29, 2015, inclusive, you may be entitled to receive a Distribution Payment from the Valeant Pharmaceuticals Fair Fund, created in the captioned proceedings (the “Fair Fund”), subject to other provisions of the Plan. For a complete list of Eligible Valeant Securities, please visit www.ValeantFairFund.com.

The administration of the Fair Fund is governed by the Plan approved by the Commission on August 22, 2024. A copy of the Plan, which contains a description of eligibility and other conditions of participation, is available at www.ValeantFairFund.com.

Determination of Recognized Claims

The amount of compensation shall be determined in accordance with the Plan of Allocation. Each Eligible Claimant’s Recognized Loss is determined by the calculations outlined in the Plan of Allocation. If the Net Available Distribution Fund is less than the sum of the Recognized Losses of all Eligible Claimants, each Eligible Claimant’s distribution amount will equal his, her or its “Pro Rata Percentage” of the Net Available Distribution Fund. If an Eligible Claimant’s Pro Rata Percentage is less than the Minimum Distribution Amount of $10, that Eligible Claimant will be deemed ineligible to receive a Distribution Payment. Further, an Eligible Claimant’s distribution amount will be no larger than his, her, or its Recognized Loss minus the amount of any compensation for the loss that resulted from the conduct described in the Order that was received from another source (e.g., class action settlement), to the extent known by the Fund Administrator (“Prior Recovery”), plus any Reasonable Interest awarded. That is, the distribution amount will be capped at the Recognized Loss less the Prior Recovery, plus any Reasonable Interest awarded.

How to Participate

If you believe you are potentially an Eligible Claimant and would like to participate, you must file your Proof of Claim Form via the online claim filing portal available at www.ValeantFairFund.com on or before the Claims Bar Date referenced below. Alternatively, you may download and complete a paper Claim Form and mail it to the address below. When submitting a claim, you must also include acceptable supporting documentation to confirm your transactions in Eligible Valeant Securities.

Claims Bar Date: January 16, 2025, 11:59 P.M. PST

Website:     

www.ValeantFairFund.com

Email:         

info@ValeantFairFund.com

Phone:       

1-888-890-6712

Address:     

Valeant Pharmaceuticals Fair Fund
c/o Verita Global
Fund Administrator 
P.O. Box 301133
Los Angeles, CA 90030-1133

 

Questions?

This Notice provides only summary information regarding the Valeant Fair Fund. We strongly recommend that you consult the documentation found at www.ValeantFairFund.com in its entirety.

Media Contact: 1-888-890-6712; info@ValeantFairFund.com

View original content:https://www.prnewswire.com/news-releases/investors-in-common-stock-and-certain-debt-securities-offered-by-valeant-pharmaceuticals-international-inc-may-be-entitled-to-payment-from-an-sec-fair-fund-302278342.html

SOURCE Valeant Fair Fund

Staff

Recent Posts

KNoW Biological Receives FDA Breakthrough Device Designation

Atlanta-based firm to begin clinical trial on advanced warning seizure monitor ATLANTA, May 13, 2025…

2 hours ago

Wincomm Wins Best Choice Award at COMPUTEX 2025 for AI-Driven Surgical Panel PC

HSINCHU, May 13, 2025 /PRNewswire/ -- Wincomm, a global leader in medical-grade computing solutions, has…

2 hours ago

Fangzhou CEO Honored at 2025 VBEF Conference as Company Showcases AI Medical Innovations

SUZHOU, China, May 13, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader…

2 hours ago

For Labbit, Semaphore Solutions Recognized in the Gartner® Market Guide for Laboratory Information Management Systems

VICTORIA, BC, May 13, 2025 /PRNewswire/ - Semaphore Solutions, a leading provider of laboratory informatics…

2 hours ago

GI Innovation and GI Biome Advance to the Semi-finals of XPRIZE Healthspan with Anti-Aging Potential of GI-102 and GIB-7 Combination Therapy

GI Innovation and GI Biome have been selected as a Top 40 semi-finalist in the XPRIZE Healthspan competition among…

8 hours ago

Tyra Biosciences to Participate at Upcoming Investor Conferences

CARLSBAD, Calif., May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology…

14 hours ago